{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:22:56Z","timestamp":1774682576670,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004465","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000}}],"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["224485\/Z\/21\/Z"],"award-info":[{"award-number":["224485\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Guidelines by the National Institute for Health and Care Excellence recommend an angiotensin receptor blocker (ARB) rather than an angiotensin-converting enzyme inhibitor (ACEi) for the treatment of hypertension for people of African and Caribbean descent, due to an increased risk of angioedema associated with ACEi use observed in US trials. However, the effectiveness and risk of these drugs in Black populations in UK routine care is unknown.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>We applied a reference trial emulation approach to UK Clinical Practice Research Datalink Aurum data (linked with data from Hospital Episode Statistics and Office for National Statistics) to study the comparative effectiveness of ARB and ACEi in ethnic minority groups in England, after benchmarking results against the ONTARGET trial. Approximately 17,593 Black, 30,805 South Asian, and 524,623 White patients receiving a prescription for ARB\/ACEi between 1 January 2001 and 31 July 2019 were included with a median follow-up of 5.2 years. The primary composite outcome was cardiovascular-related death, myocardial infarction, stroke, or hospitalisation for heart failure with individual components studied as secondary outcomes. Angioedema was a safety endpoint. We assessed outcomes using an inverse-probability\u2014weighted Cox proportional hazards model for ARB versus ACEi with heterogeneity by ethnicity assessed on the relative and absolute scale.<\/jats:p>\n<jats:p>For the primary outcome, 27,327 (18.0%) events were recorded in the ARB group (event rate: 25% per 5.5 person-years) and 80,624 (19.1%) events (event rate: 26% per 5.5 person-years) in the ACEi group. We benchmarked results against ONTARGET and observed hazard ratio (HR) 0.96 (95% CI: 0.95, 0.98) for the primary outcome, with an absolute incidence rate difference (IRD)% of -1.01 (95% CI: -1.42, -0.60) per 5.5 person-years. We found no evidence of treatment effect heterogeneity by ethnicity for the primary outcome on the multiplicative (<jats:italic>P<\/jats:italic><jats:sub><jats:italic>int<\/jats:italic><\/jats:sub> = 0.422) or additive scale (<jats:italic>P<\/jats:italic><jats:sub><jats:italic>int<\/jats:italic><\/jats:sub> = 0.287). Results were consistent for most secondary outcomes. However, for cardiovascular-related death, which occurred in 37,554 (6.6%) people, there was strong evidence of heterogeneity on the multiplicative (<jats:italic>P<\/jats:italic><jats:sub><jats:italic>int<\/jats:italic><\/jats:sub> = 0.002) and additive scale (<jats:italic>P<\/jats:italic><jats:sub><jats:italic>int<\/jats:italic><\/jats:sub> &lt; 0.001). Compared to ACEi, ARB were associated with more events in Black individuals (HR 1.20 (95% CI: 1.02, 1.40); IRD% 1.07 (95% CI: 0.10, 2.04); number-needed-to-harm (NNH): 93) and associated with fewer events in White individuals (HR 0.91 (95% CI: 0.88, 0.93); IRD% -0.87 (95% CI: -1.10, -0.63); number-needed-to-treat (NNT): 115), and no differences in South Asian individuals (HR 0.97 (95% CI: 0.86, 1.09); IRD% -0.17 (95% CI: -0.87, 0.53)). For angioedema, HR 0.56 (95% CI: 0.46, 0.67) with no heterogeneity for ARB versus ACEi on the multiplicative scale (<jats:italic>P<\/jats:italic><jats:sub><jats:italic>int<\/jats:italic><\/jats:sub> = 0.306). However, there was heterogeneity on the additive scale (<jats:italic>P<\/jats:italic><jats:sub><jats:italic>int<\/jats:italic><\/jats:sub> = 0.023). Absolute risks were higher in Black individuals (IRD% -0.49 (95% CI: -0.79, -0.18); NNT: 204) compared with White individuals (IRD% -0.06 (95% CI: -0.09, -0.03); NNT: 1667) and no difference among South Asian individuals (IRD% -0.05 (95% CI: -0.15, 0.05) for ARB versus ACEi.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>These results demonstrate variation in drug effects of ACEi and ARB for some outcomes by ethnicity and suggest the potential for adverse consequences from current UK guideline recommendations for ARB in preference to ACEi for Black individuals.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004465","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T18:00:25Z","timestamp":1726509625000},"page":"e1004465","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness and risk of ARB and ACEi among different ethnic groups in England: A reference trial (ONTARGET) emulation analysis using UK Clinical Practice Research Datalink Aurum-linked data"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2565-8525","authenticated-orcid":true,"given":"Paris J.","family":"Baptiste","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8618-7333","authenticated-orcid":true,"given":"Angel Y. S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1637-837X","authenticated-orcid":true,"given":"Anna","family":"Schultze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M.","family":"Clase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4097-4577","authenticated-orcid":true,"given":"Cl\u00e9mence","family":"Leyrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-9468","authenticated-orcid":true,"given":"Emma","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes F. E.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Cunnington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koon","family":"Teo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrikant I.","family":"Bangdiwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-9641","authenticated-orcid":true,"given":"Kevin","family":"Wing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-9493","authenticated-orcid":true,"given":"Laurie","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"10","key":"pmed.1004465.ref001","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1097\/00007611-198610000-00008","article-title":"Diabetes mellitus and hypertension in black and white populations","volume":"79","author":"JM Miller","year":"1986","journal-title":"South Med J"},{"issue":"2","key":"pmed.1004465.ref002","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/HYPERTENSIONAHA.119.14240","article-title":"High Blood Pressure and Cardiovascular Disease","volume":"75","author":"FD Fuchs","year":"2020","journal-title":"Hypertension"},{"issue":"1","key":"pmed.1004465.ref003","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12916-022-02337-w","article-title":"Ethnic differences in cardiovascular risk: examining differential exposure and susceptibility to risk factors","volume":"20","author":"FK Ho","year":"2022","journal-title":"BMC Med"},{"key":"pmed.1004465.ref004","unstructured":"UK Government. Persistent low income. In: Pensions DfWa, editor. 2022. ethnicity-facts-figures.service.gov.uk."},{"issue":"7","key":"pmed.1004465.ref005","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/jech-2015-206074","article-title":"Ethnic inequalities in limiting health and self-reported health in later life revisited","volume":"70","author":"M Evandrou","year":"2016","journal-title":"J Epidemiol Community Health"},{"key":"pmed.1004465.ref006","unstructured":"Public Health England. Local action on health inequalities: Understanding and reducing ethnic inequalities in health. PHE publications; 2018. https:\/\/assets.publishing.service.gov.uk."},{"issue":"3","key":"pmed.1004465.ref007","doi-asserted-by":"crossref","first-page":"E145","DOI":"10.1016\/S2468-2667(20)30287-5","article-title":"Ethnic inequalities in health-related quality of life among older adults in England: secondary analysis of a national cross-sectional survey","volume":"6","author":"RE Watkinson","year":"2021","journal-title":"Lancet Public Health"},{"key":"pmed.1004465.ref008","volume-title":"Ethnicity, Race and Inequality in the UK","author":"B Byrne","year":"2020"},{"key":"pmed.1004465.ref009","unstructured":"Cabinet Office. Race Disparity Audit. 2018. gov.uk."},{"issue":"3","key":"pmed.1004465.ref010","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.healthpol.2020.01.003","article-title":"Exploring the impacts of organisational structure, policy and practice on the health inequalities of marginalised communities: Illustrative cases from the UK healthcare system","volume":"124","author":"A Hui","year":"2020","journal-title":"Health Policy"},{"key":"pmed.1004465.ref011","unstructured":"Raleigh V, Holmes J. The health of people from ethnic minority groups in England. The King\u2019s Fund; 2021. kingsfund.org.uk\/publications."},{"key":"pmed.1004465.ref012","unstructured":"British Heart Foundation. South Asian background and heart health. Heart Matters. 2023. Available from: https:\/\/www.bhf.org.uk\/informationsupport\/heart-matters-magazine."},{"issue":"828","key":"pmed.1004465.ref013","article-title":"Disparities in cardiovascular disease among Caribbean populations: a systematic literature review","volume":"15","author":"DK Francis","year":"2015","journal-title":"BMC Public Health"},{"key":"pmed.1004465.ref014","unstructured":"NICE. Hypertension in adults: diagnosis and management NICE guideline [NG136]. www.nice.org.uk: NICE 2022. 2019 [updated 2022 Mar 18]. https:\/\/www.nice.org.uk\/guidance\/ng136\/resources\/hypertension-in-adults-diagnosis-and-management-pdf-66141722710213."},{"issue":"3","key":"pmed.1004465.ref015","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41371-021-00601-9","article-title":"Re-thinking the inclusion of race in British hypertension guidance","volume":"36","author":"DP Gopal","year":"2022","journal-title":"J Hum Hypertens"},{"key":"pmed.1004465.ref016","doi-asserted-by":"crossref","first-page":"m4080","DOI":"10.1136\/bmj.m4080","article-title":"First line drug treatment for hypertension and reductions in blood pressure according to age and ethnicity: cohort study in UK primary care","volume":"371","author":"SJ Sinnott","year":"2020","journal-title":"BMJ"},{"issue":"18","key":"pmed.1004465.ref017","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJM199810293391804","article-title":"Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects","volume":"339","author":"JV Gainer","year":"1998","journal-title":"N Engl J Med"},{"key":"pmed.1004465.ref018","unstructured":"National Clinical Guideline Centre. Hypertension: The clinical management of primary hypertension in adults. 2011."},{"issue":"23","key":"pmed.1004465.ref019","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"Allhat Officers Coordinators for the Allhat Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"issue":"9","key":"pmed.1004465.ref020","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1524-6175.2006.05689.x","article-title":"Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"8","author":"LB Piller","year":"2006","journal-title":"J Clin Hypertens"},{"issue":"5","key":"pmed.1004465.ref021","first-page":"481","article-title":"CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers","volume":"55","author":"J Spinar","year":"2009","journal-title":"Vnitr Lek"},{"issue":"9","key":"pmed.1004465.ref022","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1524-6175.2006.05504.x","article-title":"Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients","volume":"8","author":"MA Tedesco","year":"2006","journal-title":"J Clin Hypertens"},{"issue":"15","key":"pmed.1004465.ref023","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Ontarget Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"pmed.1004465.ref024","article-title":"Race\/ethnicity reporting and representation in US clinical trials: a cohort study","volume":"11","author":"BE Turner","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"1","key":"pmed.1004465.ref025","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1186\/s13063-020-04613-7","article-title":"Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process","volume":"21","author":"MD Witham","year":"2020","journal-title":"Trials"},{"key":"pmed.1004465.ref026","unstructured":"COUCH Health. Should diversity in clinical trials be mandatory? Discussion summary report. pmlive.com; 2021."},{"issue":"11","key":"pmed.1004465.ref027","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1161\/CIRCULATIONAHA.123.065887","article-title":"Are Recommendations That Favor Other Agents Over Angiotensin-Converting Enzyme Inhibitors in Africans With Hypertension Justified?","volume":"149","author":"JG Peter","year":"2024","journal-title":"Circulation"},{"issue":"10","key":"pmed.1004465.ref028","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/CIRCULATIONAHA.120.051718","article-title":"Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative","volume":"143","author":"JM Franklin","year":"2021","journal-title":"Circulation"},{"key":"pmed.1004465.ref029","doi-asserted-by":"crossref","first-page":"mxac011","DOI":"10.1093\/epirev\/mxac011","article-title":"Using Trial and Observational Data to Assess Effectiveness: Trial Emulation, Transportability, Benchmarking, and Joint Analysis","author":"IJ Dahabreh","year":"2023","journal-title":"Epidemiol Rev"},{"issue":"5","key":"pmed.1004465.ref030","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/EDE.0000000000001231","article-title":"Benchmarking Observational Methods by Comparing Randomized Trials and Their Emulations","volume":"31","author":"IJ Dahabreh","year":"2020","journal-title":"Epidemiology"},{"issue":"9","key":"pmed.1004465.ref031","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/aje\/kwac098","article-title":"Benchmarking Observational Analyses Before Using Them to Address Questions Trials Do Not Answer: An Application to Coronary Thrombus Aspiration","volume":"191","author":"AA Matthews","year":"2022","journal-title":"Am J Epidemiol"},{"key":"pmed.1004465.ref032","unstructured":"Clinical Practice Research Datalink. CPRD linked data. 2020. www.cprd.com\/linked-data."},{"key":"pmed.1004465.ref033","unstructured":"Clinical Practice Research Datalink. Release Notes: CPRD Aurum June 2021. cprd.com; 2021."},{"issue":"1","key":"pmed.1004465.ref034","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","article-title":"Validation and validity of diagnoses in the General Practice Research Database: a systematic review","volume":"69","author":"E Herrett","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"pmed.1004465.ref035","doi-asserted-by":"crossref","first-page":"f2350","DOI":"10.1136\/bmj.f2350","article-title":"Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study","volume":"346","author":"E Herrett","year":"2013","journal-title":"BMJ"},{"key":"pmed.1004465.ref036","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2147\/CLEP.S319245","article-title":"Quality and Completeness of Myocardial Infarction Recording in Clinical Practice Research Datalink Aurum","volume":"13","author":"R Persson","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"9","key":"pmed.1004465.ref037","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"AS Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"3","key":"pmed.1004465.ref038","doi-asserted-by":"crossref","first-page":"e051907","DOI":"10.1136\/bmjopen-2021-051907","article-title":"Effects of ACE inhibitors and angiotensin receptor blockers: protocol for a UK cohort study using routinely collected electronic health records with validation against the ONTARGET trial","volume":"12","author":"PJ Baptiste","year":"2022","journal-title":"BMJ Open"},{"key":"pmed.1004465.ref039","doi-asserted-by":"crossref","first-page":"kwae137","DOI":"10.1093\/aje\/kwae137","article-title":"Cardiorenal effects of Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET)","author":"PJ Baptiste","year":"2024","journal-title":"Am J Epidemiol"},{"issue":"4","key":"pmed.1004465.ref040","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/pubmed\/fdt116","article-title":"Completeness and usability of ethnicity data in UK-based primary care and hospital databases","volume":"36","author":"R Mathur","year":"2014","journal-title":"J Public Health (Oxf)"},{"key":"pmed.1004465.ref041","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335621","article-title":"Drug-induced angioedema","volume":"97","author":"M. Lerch","year":"2012","journal-title":"Chem Immunol Allergy"},{"issue":"15","key":"pmed.1004465.ref042","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/sim.3618","article-title":"Imputing missing covariate values for the Cox model","volume":"28","author":"IR White","year":"2009","journal-title":"Stat Med"},{"issue":"1","key":"pmed.1004465.ref043","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0962280217713032","article-title":"Propensity score analysis with partially observed covariates: How should multiple imputation be used?","volume":"28","author":"C Leyrat","year":"2019","journal-title":"Stat Methods Med Res"},{"issue":"8","key":"pmed.1004465.ref044","first-page":"CD009096","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","volume":"2014","author":"EC Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"pmed.1004465.ref045","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","article-title":"Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study","volume":"78","author":"R Chen","year":"2021","journal-title":"Hypertension"},{"issue":"6","key":"pmed.1004465.ref046","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/HYPERTENSIONAHA.108.110270","article-title":"Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors","volume":"51","author":"DR Miller","year":"2008","journal-title":"Hypertension"},{"issue":"1","key":"pmed.1004465.ref047","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(96)90161-7","article-title":"Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema","volume":"60","author":"NJ Brown","year":"1996","journal-title":"Clin Pharmcol Ther"},{"issue":"14","key":"pmed.1004465.ref048","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMsm1605385","article-title":"Per-Protocol Analyses of Pragmatic Trials","volume":"377","author":"MA Hernan","year":"2017","journal-title":"N Engl J Med"},{"key":"pmed.1004465.ref049","unstructured":"NICE. Chronic heart failure in adults: diagnosis and management nice.org.uk. 2018. https:\/\/www.nice.org.uk\/guidance\/ng106."},{"issue":"10","key":"pmed.1004465.ref050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/EBP.0000000000001391","article-title":"Does the risk of ACE-I\u2013induced angioedema differ between Black and non-Black patients","volume":"24","author":"FJ Berkey","year":"2021","journal-title":"Evidence-Based Practice"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004465","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T17:43:21Z","timestamp":1727718201000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004465","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pmed.1004465","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]}}}